“Is the expression of matrix metalloproteinases (MMP-2, -9) and tissue inhibitors of metalloproteinases (TIMP-1, -2, and -3) associated with angiogenesis and clinicopathological features for breast cancer?” (2017) Journal of Health Sciences, 7(3), pp. 158–168. doi:10.17532/jhsci.2017.460.